

Funded by the NIH • Developed at the University of Washington,  
Seattle



# Autosomal Dominant Polycystic Kidney Disease

*[ADPKD. Includes: Polycystic Kidney Disease Type 1 (PKD1), Polycystic Kidney Disease Type 2 (PKD2)]*

---

**Authors:**     **Peter C Harris, PhD**  
                      **Vicente E Torres, MD**

[About the Authors](#)

**Initial Posting:**  
**10 January 2002**

**Last Update:**  
**6 June 2006**

---

## Summary

**Disease characteristics.** [Autosomal dominant](#) polycystic kidney disease (ADPKD) is generally a late-onset, multisystem disorder characterized by bilateral renal cysts; cysts in other organs, such as the liver, seminal vesicles, pancreas, and arachnoid membrane; vascular abnormalities, such as intracranial aneurysms, dilatation of the aortic root, and dissection of the thoracic aorta; mitral valve prolapse; and abdominal wall hernias. The renal manifestations of ADPKD include renal function abnormalities, hypertension, renal pain, and renal insufficiency. Approximately 50% of individuals with ADPKD have end-stage renal disease (ESRD) by age 60 years. Polycystic liver disease is the most common extrarenal manifestation of ADPKD. The prevalence of liver cysts in individuals with ADPKD increases from 20% in the third decade to approximately 75% after the sixth decade. Intracranial aneurysms occur in approximately 10% of individuals with ADPKD. The prevalence is higher in those with a positive [family history](#) of aneurysms or subarachnoid hemorrhage (22%) than in those without (6%). Mitral valve prolapse is the most common valvular abnormality and has been demonstrated in up to 25% of [affected](#) individuals. Substantial variability of severity of renal disease and other extra-renal manifestations occurs even within the same family.

**Diagnosis/testing.** The diagnosis of ADPKD is established primarily by imaging studies of the kidneys. Diagnostic criteria for individuals known to be at 50% risk for the disease include: at least two unilateral or bilateral cysts in individuals younger than age 30 years; two cysts in each kidney in individuals age 30-59



years; and four cysts in each kidney in individuals age 60 years or older. The [sensitivity](#) of the criteria is nearly 100% for all individuals with ADPKD who are age 30 years or older and for younger individuals with *PKD1* mutations; these criteria are only 67% sensitive for individuals with *PKD2* [mutations](#) who are younger than age 30 years. Large echogenic kidneys without distinct macroscopic cysts in an infant/child at 50% risk for ADPKD are diagnostic. In the absence of a [family history](#) of ADPKD, the presence of bilateral renal enlargement and cysts, with or without the presence of hepatic cysts, and the absence of other manifestations suggestive of a different renal cystic disease provide presumptive, but not definite, evidence for the diagnosis. In 85% of individuals, ADPKD is caused by [mutations](#) in the [gene](#) *PKD1*; in 15% of individuals [mutations](#) in *PKD2* are causative. [Sequence analysis](#) of the *PKD1* and *PKD2* [genes](#) is clinically available, with a detection rate for [disease-causing mutations](#) of approximately 85%.

**Management.** Current therapy for ADPKD is directed towards reducing the morbidity and mortality from the renal and extrarenal complications of the disease. Treatment for hypertension may include administration of ACE inhibitors and diet modification. Conservative treatment of flank pain is recommended; options include non-opioid agents, tricyclic antidepressants, narcotic analgesics, splanchnic nerve blockade, and renal denervation. More aggressive treatments include cyst decompression with cyst aspiration and sclerosis. In individuals with many cysts contributing to pain, laparoscopic or surgical cyst fenestration may be of benefit. Episodes of cyst hemorrhage or of gross hematuria are usually self-limited and respond well to conservative management with bed rest, analgesics, and adequate hydration to prevent development of obstructing clots. Treatment of nephrolithiasis is the same as that for individuals without ADPKD. Treatment of cyst infections is difficult - therapeutic agents of choice include trimethoprim-sulfamethoxazole, fluoroquinolones, and chloramphenicol. Therapeutic interventions aimed at slowing the progression of renal failure include control of hypertension and hyperlipidemia, dietary [protein](#) restriction, control of acidosis, and prevention of hyperphosphatemia. For ruptured or symptomatic intracranial aneurysm, the mainstay of therapy is surgical clipping of the ruptured aneurysm at its neck. For individuals with high surgical risk or with technically difficult-to-manage lesions, endovascular treatment with detachable platinum coils may be indicated. Surveillance includes MRI [screening](#) for intracranial aneurysms.

**Genetic counseling.** ADPKD is inherited in an [autosomal dominant](#) manner. Every child of an [affected](#) individual has a 50% chance of inheriting the [mutation](#). The risk to sibs of the [proband](#) depends upon the genetic status of the parents; if a parent is [affected](#), the risk to sibs is 50%. The vast majority of individuals with ADPKD have a parent with ADPKD, but *de novo* [mutations](#) occur in about 10% of [affected](#) individuals. [Prenatal testing](#) for ADPKD is clinically available if the [mutation](#) has been identified in an [affected](#) family member or if [linkage](#) has been established in the family. Requests for [prenatal testing](#) for adult-onset conditions such as ADPKD that do not affect intellect and have some treatment available are not common.



## Diagnosis

### Clinical Diagnosis

**Autosomal dominant** polycystic kidney disease (ADPKD) is a multisystem disorder characterized by the following:

- Bilateral renal cysts <sup>a, b</sup>
- Cysts in other organs, such as the liver, seminal vesicles, pancreas, and arachnoid membrane
- Extrarenal abnormalities, such as intracranial aneurysms and dolichoectasias, dilatation of the aortic root and dissection of the thoracic aorta, mitral valve prolapse, and abdominal wall hernias
- The absence of manifestations suggestive of a different renal cystic disease

- a. Diagnostic criteria relying on sonographic findings for individuals known to be at 50% risk for the disease include [[Ravine et al 1994](#)]:
- At least two unilateral or bilateral cysts in individuals younger than age 30 years
  - Two cysts in each kidney in individuals age 30-59 years
  - Four cysts in each kidney in individuals age 60 years or older

The **sensitivity** of these criteria is nearly 100% [[Nicolau et al 1999](#)] for:

- All individuals with ADPKD who are age 30 years or older
- Younger individuals with *PKD1* **mutations**

The **sensitivity** of these criteria is 67% for individuals with *PKD2* **mutations** who are younger than age 30 years [[Nicolau et al 1999](#)].

- b. Large echogenic kidneys without distinct macroscopic cysts in an infant/child at 50% risk for ADPKD are diagnostic.

Note:

1) In an individual with a positive **family history** of ADPKD:

- ◆ The enlargement of the kidneys or liver on physical examination is highly suggestive for the diagnosis.
- ◆ The presence of hypertension, mitral valve prolapse, or abdominal wall hernia is suggestive of the diagnosis. Definite diagnosis, however, relies on imaging or **molecular genetic testing**.

2) In the absence of a **family history** of ADPKD, the presence of bilateral renal enlargement and cysts with or without the presence of hepatic cysts, and the absence of other manifestations suggestive of a different renal cystic disease provide presumptive, but not definite, evidence for the diagnosis.

### Molecular Genetic Testing

*GeneReviews designates a molecular genetic test as clinically available only if the test is listed in the GeneTests Laboratory Directory by at least one US CLIA-certified laboratory or a clinical laboratory outside the US. GeneTests does not independently verify information provided by laboratories and does not warrant any aspect of a laboratory's work. Listing in GeneTests does not imply that laboratories are in compliance with accreditation, licensure, or patent laws. Clinicians must communicate directly with the laboratories to verify*



information. —ED.

**Genes.** Two [genes](#) are known to be associated with ADPKD:

- *PKD1*, accounting for approximately 85% of [affected](#) individuals
- *PKD2*, accounting for approximately 15% of [affected](#) individuals

**Other loci.** At least one further [locus](#) representing a small fraction of families not linked to either the *PKD1* or *PKD2* [locus](#) is hypothesized.

### Molecular genetic testing: Clinical uses

- **Confirmation of diagnosis.** The diagnosis of ADPKD is established primarily by imaging studies of the kidneys; however, in some individuals, [molecular genetic testing](#) can be used to confirm or establish the diagnosis when it is uncertain.
- **Presymptomatic diagnosis.** Molecular genetic testing can be used for presymptomatic diagnosis when imaging results are equivocal and/or when a definite diagnosis is required in a younger individual, such as a potential living related kidney donor.
- **Prenatal diagnosis and preimplantation genetic diagnosis.** Molecular testing for [prenatal diagnosis](#) or [preimplantation diagnosis](#) is not usually requested for ADPKD because the disease usually first occurs in adulthood. A possible exception are rare families in which severe, early-onset disease in one child suggests a significant [risk of recurrence](#) of severe disease in a sibling [[Zerres et al 1993](#)].

### Molecular genetic testing: Clinical methods

- **Linkage analysis.** Presymptomatic testing is possible in larger families by [linkage analysis](#) using highly informative [microsatellite markers](#) flanking the *PKD1* and *PKD2* [genes](#). A significant drawback with [linkage analysis](#) is the need for a relatively large number of [affected](#) family members in order to establish which of the two possible [genes](#) is the responsible one within each family. [Linkage](#) studies are based upon accurate clinical diagnosis of ADPKD in the [affected](#) family members, understanding of the genetic relationships in the family, and the availability and willingness of family members to be tested. Because of these constraints, [linkage analysis](#) is probably suitable in fewer than 50% of families, but is accurate if all the provisos outlined above are met. [Linkage](#) testing is not available to families with a single [affected](#) individual and [linkage](#) testing may be complicated if a *de novo* [mutation](#) has occurred recently in the family.
- **Sequence analysis.** The large size and complexity of the *PKD1* [gene](#), as well as marked [allelic heterogeneity](#), have presented obstacles to [molecular testing](#) by [direct DNA analysis](#). Detection rates by direct [sequencing](#) are now approximately 85% [[Rossetti, manuscript in preparation](#)].
- **FISH/genomic microarray analysis.** These methods are of limited diagnostic value in ADPKD because of the [genomic duplication](#) of much of the [gene](#) and because only approximately 3% of *PKD1* [mutations](#) are large [deletions](#) [[European Polycystic Kidney Disease Consortium 1994](#) , [Ariyurek et al 2004](#)].



**Molecular genetic testing: Research.** Use of [mutation scanning](#) by methods such as DHPLC in research settings has yielded [mutation](#) detection rates of approximately 65-70% for *PKD1* and *PKD2*.

[Table 1](#) summarizes [molecular genetic testing](#) for this disorder.

**Table 1. Molecular Genetic Testing Used in ADPKD**

Gene	Test Method	Mutations Detected	Mutation Detection Rate	Test Availability
PKD1	FISH/genomic microarray analysis	PKD1 deletions	Very low <sup>1</sup>	Clinical Testing
	Sequence analysis	PKD1 sequence alterations	~85% <sup>2</sup>	
PKD2		PKD2 sequence alterations		Clinical Testing

1. Communication with laboratories performing the analysis [Rossetti, in preparation]

2. [Veldhuisen et al 1997](#) ; [Rossetti et al 2001](#) ; [Rossetti, Chauveau et al 2002](#)

**Interpretation of test results.** For issues to consider in interpretation of sequence analysis results, click [here](#).

As most [mutations](#) are unique and up to one-third of *PKD1* changes are missense, the pathogenicity of some changes is difficult to prove.

### Testing Strategy for a Proband

1. Kidney imaging methods such as abdominal ultrasound, CT, or MR should be considered first for diagnosis.
2. [Molecular genetic testing](#) by [sequence analysis](#) can be helpful when the imaging results are equivocal and/or when a definite diagnosis is required in a younger adult.
3. [Screening](#) for larger [rearrangements](#) using FISH/genomic microarray analysis in a [proband](#) with ADPKD detects only a few [mutations](#).

### Genetically Related (Allelic) Disorders

No other disorders are known to be associated with [mutations](#) in the *PKD1* or *PKD2* genes.

A [contiguous gene syndrome](#) in which *PKD1* and the adjacent [tuberous sclerosis complex gene](#), *TSC2*, are disrupted by [deletion](#) has been described [[Sampson et al 1997](#)]. In individuals with this syndrome, the [phenotype](#) of tuberous sclerosis and severe polycystic kidney disease is usually evident in utero or is diagnosed in infancy.

## Clinical Description

### Natural History

### Renal Manifestations



Although all individuals with ADPKD develop cysts within the kidneys, substantial variability occurs in severity of renal disease and other manifestations of this disease even within the same family. Genetic heterogeneity, [mutation](#) position in *PKD1* modifier [genes](#) and environmental factors account for this variability. The renal manifestations of ADPKD include renal function abnormalities, hypertension, renal pain, and renal insufficiency.

**Renal function abnormalities.** Reduction in urinary concentrating capacity and excretion of ammonia occur early and may result from the disruption of the renal architecture by the cysts, interference with the countercurrent exchange and multiplication mechanisms, and defective trapping of solutes and ammonia in the renal medulla. In the early stages of the disease, these defects are moderate and significant overlap exists between [affected](#) and [unaffected](#) individuals. Although the concentrating defect may not have clinical consequences, the reduction of urinary excretion of ammonia in the presence of metabolic stresses, such as dietary indiscretions, may contribute to the development of uric acid and calcium oxalate stones, which, in association with low urine pH values and hypocitric aciduria, occur with increased frequency in individuals with ADPKD [[Torres, Keith et al 1994](#)]. Glomerular hyperfiltration has also been described early in the course of ADPKD [[Wong et al 2004](#)].

**Hypertension.** Another early functional abnormality is a reduction in renal blood flow, which can be detected in young individuals, when systolic and diastolic blood pressures are still normal, and precedes the development of hypertension [[Chapman et al 1990](#) ; [Torres et al 1991](#) ; Torres, personal observation]. Hypertension usually develops before any decline in glomerular filtration rate (GFR). It is characterized by the following:

- An increase in renal vascular resistance and filtration fraction
- Normal or high peripheral plasma renin activity
- Resetting of the pressure-natriuresis relationship
- Salt [sensitivity](#)
- Normal or increased extracellular fluid volume, plasma volume, and cardiac output
- Partial correction of renal hemodynamics and sodium handling by converting-enzyme inhibition

Hypertension in individuals with ADPKD may lead to end-organ damage, increase the morbidity and mortality from associated vascular and cardiac defects, and cause fetal and maternal complications during pregnancy [[Chapman et al 1994](#)].

**Renal pain.** Pain is a common manifestation of ADPKD [[Segura et al 1996](#)]. Potential etiologies include cyst hemorrhage, nephrolithiasis, cyst infection, and rarely, tumor. Discomfort, ranging from a sensation of fullness to severe pain, can also result from renal enlargement and distortion by the cysts. Gross hematuria can occur in association with complications such as cyst hemorrhage and nephrolithiasis or as an [isolated](#) event. Passage of clots can also be a source of pain. A cyst hemorrhage can be accompanied by fever, possibly caused by cyst infection. Most often the pain is self-limited and resolves within two to seven days. Rarely, pain may be caused by retroperitoneal bleeding, which may be severe and require transfusion.

**Nephrolithiasis.** The prevalence of renal stone disease in individuals with ADPKD is approximately 20% [[Torres et al 1993](#)]. The majority of stones are composed of uric acid and/or calcium oxalate. Urinary stasis thought to be secondary to



distorted renal anatomy and metabolic factors plays a role in the pathogenesis.

Predisposing factors to the development of renal stone disease in ADPKD include decreased ammonia excretion, low urinary pH, and low urinary citrate concentration.

**Urinary tract infection and cyst infection.** In the past, the incidence of urinary tract infection may have been overestimated in individuals with ADPKD because of the frequent occurrence of sterile pyuria. As in the general population, females experience urinary tract infection more frequently than males and the majority of infections are caused by *E. coli* and other enterobacteriaceae [Elzinga & Bennett 1996]. Retrograde infection from the bladder may lead to pyelonephritis or cyst infection.

**Renal cell carcinoma (RCC).** RCC does not occur more frequently in individuals with ADPKD than in the general population. Nevertheless, when RCC develops in individuals with ADPKD, it has a different biologic behavior, including earlier age of presentation, frequent constitutional symptoms, and a higher proportion of sarcomatoid, bilateral, multicentric, and metastatic tumors; males with ADPKD are not more likely to develop RCC than are females with ADPKD [Keith et al 1994].

**Other.** Massive renal enlargement can cause complications resulting from compression of local structures, such as inferior vena cava compression and gastric outlet obstruction (mainly by cysts of the right kidney).

**Renal failure.** Approximately 50% of individuals with ADPKD have end-stage renal disease (ESRD) by age 60 years [Gabow 1996]. Once renal insufficiency has begun, the average yearly rate of decline in GFR is approximately 5 mL/min [Klahr et al 1995]. Compression of the normal renal parenchyma by expanding cysts, vascular sclerosis, interstitial inflammation and fibrosis, and apoptosis of the tubular epithelial cells are the causative mechanisms.

Genetic background and environmental factors account for significant [intrafamilial variability](#) in disease severity. [PKD1 mutations](#) are associated with a 20-year earlier onset of ESRD than [PKD2 mutations](#) [Hateboer et al 1999]. In PKD2, males progress to ESRD more rapidly than females [Magistroni et al 2003], but no gender difference is seen in PKD1 [Hateboer et al 1999 ; Rossetti, Burton et al 2002]. Other risk factors include diagnosis before age 30 years, first episode of hematuria before age 30 years, onset of hypertension before age 35 years, hyperlipidemia, low concentration of high-density lipoprotein (HDL) cholesterol, and presence of sickle cell trait [Gabow 1996]. Whether African-Americans or individuals with specific [genotypes](#) of the *ACE* or *ENOS* [genes](#) are at an increased risk for disease progression is controversial.

## Extrarenal Manifestations

**Polycystic liver disease** is the most common extrarenal manifestation of ADPKD. The severity of polycystic liver disease usually parallels that of polycystic kidney disease, but exceptions are common.

The prevalence of liver cysts in individuals with ADPKD increases from 20% in the third decade to approximately 75% after the sixth decade [Torres 1996]. Polycystic liver disease develops at a younger age in women and is more severe in women who have had multiple pregnancies. After menopause, the size of the



liver cysts increases in those women who receive estrogen replacement therapy, suggesting that estrogens have an important effect on the progression of polycystic liver disease [[Sherstha et al 1997](#)].

Liver cysts are usually asymptomatic and never cause liver failure. Symptoms, when they occur, are caused by the mass effect of the cysts, the development of complications, or rare associations. Mass effects include abdominal distention and pain, early satiety, dyspnea, and low back pain. Liver cysts can also cause extrinsic compression of the inferior vena cava (IVC), hepatic veins, or bile ducts [[Torres, Rastogi et al 1994](#)].

Complications of polycystic liver disease include cyst hemorrhage, infection, or rupture. Hemorrhagic cysts may cause fever and masquerade as cholecystitis or cyst infection. Infected cysts cause localized pain or tenderness, fever, leukocytosis, elevated erythrocyte sedimentation rate, and high serum concentration of alkaline phosphatase. CT scan and MRI are helpful in the diagnosis of cyst infection but have low [specificity](#). White blood cell scans are more specific but not always conclusive [[Telenti et al 1990](#)]. The rupture of a hepatic cyst can cause acute abdominal pain and ascites.

### Other liver disease

- Dilatation of biliary ducts may be associated with episodes of cholangitis.
- [Congenital](#) hepatic fibrosis is very rare in individuals with ADPKD.
- Cholangiocarcinoma is infrequently associated with ADPKD.

**Pancreatic lesions.** Pancreatic cysts occur in approximately 8% of individuals with ADPKD. They are usually less prominent than those observed in [von Hippel-Lindau disease](#). Some authors have reported an association between ADPKD and pancreatic neoplasms [[Naitoh et al 2005](#)]; however, these cases may represent chance associations of two common disorders.

**Vascular and cardiac manifestations.** The most important non-cystic manifestations of ADPKD include intracranial and other arterial aneurysms, and more rarely, dolichoectasias, dilatation of the aortic root, dissection of the thoracic aorta and cervicocephalic arteries, abnormalities of the cardiac valves, and possibly coronary artery aneurysms [[Pirson et al 2002](#)]. Evidence also exists of [familial](#) clustering of thoracic aortic dissections in ADPKD.

Intracranial aneurysms occur in approximately 10% of individuals with ADPKD [[Pirson et al 2002](#)]. The prevalence is higher in those with a positive [family history](#) of intracranial or subarachnoid hemorrhage (22%) than in those without (6%). The majority of intracranial aneurysms are asymptomatic. Focal findings such as cranial nerve palsy or seizure may result from compression of local structures by an enlarging aneurysm.

The mean age of rupture of intracranial aneurysms is lower in individuals with ADPKD than in the general population (age 39 years versus age 51 years).

The risk of rupture of asymptomatic intracranial aneurysms depends on whether there is a history of rupture from a different site [[International Study of Unruptured Intracranial Aneurysms Investigators 1998](#)]. In the absence of such history, the risk is 0.05% per year for aneurysms smaller than 10 mm in diameter, about 1% per year from aneurysms measuring 10-24 mm, and 6% within one year for those measuring 25 mm or larger. When a previous history of



rupture from a different site exists, the risk of rupture is 0.5-1% per year regardless of size.

The risk of rupture of symptomatic aneurysms is higher, approximately 4% per year.

Intracranial aneurysm rupture carries a 35-55% risk of combined severe morbidity and mortality at three months [Inagawa 2001]. At the time of rupture of an aneurysm, most individuals have normal renal function and up to 30% have normal blood pressure.

Follow-up studies of individuals with ADPKD with intracranial aneurysms found a moderate risk for the development of new aneurysms or enlargement of an existing one in previously symptomatic individuals and a low risk of enlargement of asymptomatic aneurysms detected by presymptomatic screening [Belz et al 2003 , Gibbs et al 2004].

Mitral valve prolapse is the most common valvular abnormality and has been demonstrated by echocardiography in up to 25% of individuals with ADPKD.

Several studies have shown increased left ventricular mass, left ventricular diastolic dysfunction, endothelial dysfunction, increased carotid intima-media thickness, and exaggerated blood pressure response during exercise even in young normotensive individuals with ADPKD with well-preserved renal function. Even normotensive individuals with ADPKD may show significant biventricular diastolic dysfunction, suggesting cardiac involvement early in the course of the disease [Martinez-Vea et al 2004 , Oflaz et al 2005]. The clinical significance of this finding remains to be determined.

## Genotype-Phenotype Correlations

**Heterozygotes.** A clear association exists between the severity of renal disease and the [gene](#) involved (*PKD1* or *PKD2*).

[Mutations](#) in *PKD1* are associated with more severe disease with an earlier age at diagnosis and mean age of onset of end-stage renal disease (ESRD) (54.3 years for *PKD1*; 74.0 years for *PKD2*) [Hateboer et al 1999]. Therefore, while most individuals with [mutations](#) associated with *PKD1* experience renal failure by age 70 years, more than 50% of individuals with [mutations](#) in *PKD2* have adequate renal function at that age.

Two individuals in one family who were [double heterozygotes](#) for both a *PKD1* and a *PKD2* [mutation](#) had more severe renal disease, but lived into adulthood [Pei et al 2001].

The extrarenal manifestations of ADPKD are associated with both [genes](#). Evidence has shown that [mutations](#) in both *PKD1* and *PKD2* are associated with increased risk for intracranial aneurysms [Rossetti et al 2003].

Studies have analyzed whether the type or position of the [mutation](#) within the *PKD1* or *PKD2* [gene](#) correlates with the resulting [phenotype](#). Significant intrafamilial [phenotypic](#) variability is seen, both in the severity of renal disease and the array of extrarenal manifestations, indicating that genetic modifiers and the environment significantly influence the disease presentation and course.

Analysis of the [phenotypic](#) variability in renal function between monozygotic twins



and siblings supports the role of genetic modifying factors [Persu et al 2004]. Recent studies estimate that 18-59% of the variance in age to ESRD may result from heritable modifying factors [Fain et al 2005 , Paterson et al 2005].

Among individuals with *PKD1* mutations, interfamilial phenotypic differences have been documented and data indicates that the position of the mutation may correlate with the severity of the disease [Rossetti, Burton et al 2002]. Familial clustering of intracranial aneurysms has also been recorded and a recent study showed that mutations in the 5' half of *PKD1* are more likely to result in the development of intracranial aneurysms than 3' changes [Rossetti et al 2003]. These associations with mutation position may result from the cleavage of polycystin-1 into more than one protein product [Qian et al 2002]. No clear correlations with mutation type or position were found in *PKD2* [Magistroni et al 2003].

**Homozygotes.** The embryonic lethal phenotype (with cystic kidneys) of homozygous *Pkd1* or *Pkd2* knockout mice [Lu et al 1997 , Wu et al 2000] suggests that the corresponding homozygous or compound heterozygous genotype in humans would be incompatible with live birth. Consistent with this, a consanguineous family in which both parents were affected with PKD1 had two spontaneous miscarriages at four and six months' gestation, although fetal tissue for histologic analysis was not available [Paterson et al 2002].

## Penetrance

**Cyst development.** Penetrance of ADPKD is very high with practically all older adults with a *PKD1* or *PKD2* mutation developing multiple bilateral cysts. Because the disease is progressive, few cysts may be evident during childhood or young adulthood, especially for PKD2.

**ESRD.** Penetrance is reduced for ESRD. While the majority of individuals with PKD1 experience ESRD during their lifetime, many individuals with PKD2 (especially females) have adequate renal function into old age.

## Anticipation

Anticipation has been suggested in ADPKD; however, natural history studies reveal that despite considerable intrafamilial phenotypic variability, parent-child pairs are as likely to show more severe disease in the parent as in the child [Geberth et al 1995].

## Nomenclature

A term for ADPKD that is no longer in use is adult polycystic kidney disease (APKD).

## Prevalence

ADPKD is the most common potentially lethal single-gene disorder. Its prevalence at birth is between 1:400 and 1:1,000 and it affects approximately 400,000 persons in the United States [Iglesias et al 1983]. Approximately 1,800 individuals start renal replacement therapy every year.

ADPKD occurs worldwide and in all races consistent with a significant level of *de novo* mutation [Rossetti et al 2001]. In the United States, the percentage of



end-stage renal disease (ESRD) attributable to ADPKD is less among African-Americans than among Caucasians, but this reflects a higher incidence of other causes of ESRD among African-Americans.

## Differential Diagnosis

*For current information on availability of genetic testing for disorders included in this section, see [GeneTests Laboratory Directory](#). —Ed.*

In the absence of a [family history](#) of the disease or in the presence of atypical presentations, benign simple cysts and other cystic diseases should be considered in the differential diagnosis.

The prevalence of simple renal cysts (at least one renal cyst) in disease-free individuals studied by ultrasound examination is 0% in those age 15-29 years, 1.7% in those age 30-49 years, 11.5% in those age 50-70 years, and 22.1% in those age 70 years or older. The prevalence of bilateral renal cysts (at least one in each kidney) is 1% in those age 30-49 years, 4% in those age 50-69 years, and 9% in those age 70 years or older [[Ravine et al 1993](#)].

Simple hepatic cysts occur in 2.5% to 4.6% of individuals referred for abdominal ultrasound examination. They are more common among women than men and increase in frequency with age. The majority of simple hepatic cysts are solitary and no more than three cysts are present in those with multiple cysts [[Gaines & Sampson 1989](#)].

Renal cystic diseases that are occasionally confused with ADPKD include [autosomal recessive](#) polycystic kidney disease, tuberous sclerosis complex (TSC), von Hippel-Lindau (VHL) syndrome, oral-facial-digital syndrome type 1, glomerulocystic kidney disease, Hajdu-Cheney syndrome, other malformation or disruption syndromes, localized renal cystic disease, and acquired renal cystic disease. In many individuals [affected](#) with one of these disorders, the establishment of the correct diagnosis depends on the appropriate identification of characteristic extrarenal manifestations.

**[Autosomal recessive polycystic kidney disease \(ARPKD\)](#)** is characterized by various combinations of bilateral renal cystic disease resulting from the fusiform dilatation of the collecting tubules and [congenital](#) hepatic fibrosis. [Congenital](#) hepatic fibrosis or biliary dysgenesis is a developmental abnormality that leads to portal hypertension and is characterized by enlarged and fibrotic portal areas with apparent proliferation of bile ducts, absence of central bile ducts, hypoplasia of the portal vein branches, and sometimes prominent fibrosis around the central veins. Individuals with ARPKD have [unaffected](#) parents, whereas individuals with ADPKD usually have an [affected](#) parent. In a minority of individuals, ARPKD can present later in childhood or adulthood with significant liver disease and focal cystic renal disease similar to ADPKD [[Adeva et al 2006](#)].

**[Tuberous sclerosis complex](#)** is an [autosomal dominant](#) disorder often associated with abnormalities of the skin, brain, heart and kidneys. Renal findings include renal angiomyolipomas, renal cysts, and less frequently, renal cell carcinoma. The coexistence of renal cysts and angiomyolipomas is pathognomonic for tuberous sclerosis complex. However, renal cysts can occur in the absence of angiomyolipomas, particularly in the first year of life. In these cases, the radiographic findings mimic those of ADPKD.



**Von Hippel-Lindau syndrome** is an [autosomal dominant](#) disorder that manifests with retinal and/or central nervous system hemangioblastomas, renal cysts, renal cell carcinoma, pancreatic cysts, pheochromocytomas, and papillary cystadenomas of the epididymis. Renal cysts are usually multiple and bilateral and often associated with multiple solid tumors. In the absence of solid tumors, the appearance of the kidneys in von Hippel-Lindau disease may mimic that of ADPKD.

**Oral-facial-digital syndrome type 1** is a rare [X-linked dominant](#) disorder that is lethal in males. [Affected](#) females may have kidneys that are indistinguishable from those seen in ADPKD. Liver cysts may also be present. The correct diagnosis should be suggested by the extrarenal manifestations, including oral abnormalities, such as hyperplastic frenula, cleft tongue, cleft palate or lip, and malposed teeth; facial abnormalities, such as broad nasal root with hypoplasia of nasal alae and malar bone; and digital abnormalities.

**Glomerulocystic kidney disease** is a term used to describe a poorly defined disease or group of diseases characterized by the predominance of glomerular cysts, absence of or minimal tubular involvement and lack of urinary tract obstruction, renal dysplasia, or evidence of a recognizable cystic disease or malformation syndrome. Most of the individuals initially described who met this definition were infants or young children without a [family history](#) of renal disease presenting with enlarged kidneys or variable degrees of renal insufficiency. More recently, this disease has been described in children and adults from families with an [autosomal dominant pattern of inheritance](#). [Linkage analysis](#) in two of these families has shown that it is not PKD1 or PKD2 [[Sharp et al 1997](#)].

**Hajdu-Cheney syndrome.** Renal enlargement with cortical and medullary cysts with or without impairment of renal function can occur in individuals with Hajdu-Cheney syndrome. This rare [autosomal dominant](#) disorder is characterized by short stature, midfacial flattening with proptosis, receding chin, hirsutism, acro-osteolysis of terminal phalanges, and basilar invagination of the skull.

**Localized renal cystic disease** is characterized by the cystic degeneration of a portion of one kidney with a histologic appearance that strongly resembles that of advanced ADPKD, but that is neither progressive nor [familial](#). This entity should be differentiated from asymmetric presentation of ADPKD as well as from other lesions such as multilocular cystic nephroma, cystic renal cell carcinoma, and segmental multicystic renal dysplasia.

**Acquired renal cystic disease** refers to the cystic degeneration of the renal parenchyma that occurs in ESRD. [Affected](#) individuals are often asymptomatic; occasionally, complications such as hematuria, hemorrhage into cysts, cyst rupture with retroperitoneal hemorrhage, cyst infection, and development of adenomas or carcinomas can occur.

**Autosomal dominant polycystic liver disease (ADPLD)** without kidney involvement, an inherited disorder distinct from ADPKD, appears to be genetically heterogenous [[Reynolds et al 2000](#) , [Qian et al 2003](#) , [Tahvanainen et al 2003](#)]. Two [genes](#), *PRKCSH* and *SEC63* (6q21) have been identified [[Drenth et al 2003](#) , [Li et al 2003](#) , [Davila et al 2004](#)].

## Management

### Evaluations at Initial Diagnosis to Establish the Extent of Disease



- **Renal ultrasound examination**, helpful in [screening](#) all individuals except those with a *PKD2* [mutation](#) who are younger than age 30 years. In those individuals, CT or MRI is preferable because of the low [sensitivity](#) of renal ultrasound examination.
- **CT of the abdomen without and with contrast enhancement** to help determine the extent of cystic disease in the kidneys and liver and estimating the prognosis. CT, but not MRI, can detect stones and parenchymal calcifications. CT or MR angiography can be used when visualization of the renal arteries is necessary. MRI can be used when administration of iodinated contrast material is contraindicated.
- **Standardized blood pressure [screening](#)** per the recommendations of the American Heart Association to detect early stages of hypertension. When "white coat" hypertension (i.e., blood pressure that is elevated when measured in the clinic, but normal when measured outside of the clinic) is suspected, two-hour ambulatory blood pressure monitoring is appropriate.
- **Measurement of blood lipid concentrations** because hyperlipidemia is a correctable risk factor for progressive renal disease, including ADPKD
- **Urine studies** to detect the presence of microalbuminuria or proteinuria, which in the presence of severe renal cystic disease indicates a worse prognosis and mandates strict control of the blood pressure
- **Echocardiography** in persons with heart murmurs or systolic clicks possibly resulting from valvular heart disease, mitral valve prolapse or [congenital](#) cardiac abnormalities
- **Echocardiography or cardiac MRI** to [screen](#) persons at high risk because of a [family history](#) of thoracic aortic dissections
- **Head MRA or CT angiography** to [screen](#) persons at high risk because of a [family history](#) of intracranial aneurysms (Screening for intracranial aneurysms in individuals without a [family history](#) of intracranial aneurysms is not recommended.)

## Treatment of Manifestations

Current therapy for ADPKD is directed towards reducing the morbidity and mortality from the renal and extrarenal complications of the disease.

**Hypertension.** The antihypertensive agent(s) of choice in ADPKD has not been clearly established. Because of the role of the renin angiotensin system in the pathogenesis of hypertension in ADPKD, ACE inhibitors and angiotensin II receptor antagonists may be superior to other agents in individuals with preserved renal function. ACE inhibitors and angiotensin II receptor blockers increase renal blood flow, have a low side-effect profile, and may reduce vascular smooth muscle proliferation and development of atherosclerosis.

- The administration of ACE inhibitors, but not the administration of calcium channel blockers, has been shown to reduce microalbuminuria in individuals with ADPKD [[Ecdar & Schrier 2001](#)].
- In a historic non-randomized study, the administration of ACE inhibitors without diuretics was found to result in a lower rate of decline in glomerular



filtration rate (GFR) and less proteinuria than the administration of a diuretic without an ACE inhibitor for similar control of blood pressure [Ecdar & Schrier 2001].

- A recent study found no renal protective effect of an ACE inhibitor over a  $\beta$ -blocker [van Dijk et al 2003], while another found that more rigorous blood pressure control did not preserve renal function, although it did lead to a greater decrease in left ventricular mass [Schrier et al 2002].
- A long-term follow-up of the Modification of Diet in Renal Disease (MDRD) study showed that individuals with ADPKD randomized to a low blood pressure target (MAP <92 mmHg) experienced significantly less ESRD and combined ESRD/death than those randomized to the usual blood pressure target (MAP <107 mmHg) [Sarnak et al 2005].

**Flank pain.** After excluding causes of flank pain that may require intervention, such as infection, stone, or tumor, an initial conservative approach to pain management is best.

- **Nonopioid agents** are preferred and care should be taken to avoid long-term administration of nephrotoxic agents such as combination analgesic and nonsteroidal anti-inflammatory drugs.
- **Tricyclic antidepressants** are helpful, as in all chronic pain syndromes, and are well tolerated.
- **Narcotic analgesics** should be reserved for the management of acute episodes, as chronic use can lead to physical and psychologic dependence.
- **Splanchnic nerve blockade** with local anesthetics or steroids can result in pain relief beyond the duration of the local anesthetic.
- **Renal denervation** via a thoracoscopic approach was successful in one affected individual [Chapuis et al 2004].

When conservative measures fail, therapy can be directed toward cyst decompression with cyst aspiration and sclerosis.

- **Cyst aspiration**, under ultrasound or CT guidance, is a relatively simple procedure carried out routinely by interventional radiologists. Complications from aspiration of centrally located cysts are more common, and the morbidity of the procedure is proportional to the number of cysts treated.
- **Sclerosing agents** such as 95% ethanol or acidic solutions of minocycline are commonly used to prevent the reaccumulation of cyst fluid. Excellent results have been obtained with 95% ethanol, achieving a success rate of 90% in benign renal cysts. Minor complications include microhematuria, localized pain, transient fever, and systemic absorption of the alcohol. More serious complications such as pneumothorax, perirenal hematoma, arteriovenous fistula, urinoma, and infection are rare [Segura et al 1996].

In individuals with many cysts contributing to pain, laparoscopic or surgical cyst fenestration through lumbotomy or flank incision may be of benefit.

- **Surgical decompression** was effective in 80-90% of individuals for one year and 62-77% had sustained pain relief for longer than two years [Elzinga et al 1992]. Surgical intervention does not accelerate the decline in renal function, but neither does it appear to preserve declining renal function.



- **Laparoscopic fenestration** has been shown to be as effective as open surgical fenestration in short-term follow-up for individuals with limited disease, and has a shorter, less complicated recovery period.
- **Laparoscopic and retroperitoneoscopic nephrectomy and arterial embolization** have been used to treat symptomatic polycystic kidneys in individuals with ADPKD who have ESRD [[Ubara et al 1999](#) , [Dunn et al 2000](#)].
- **Hand-assisted laparoscopic nephrectomy** may be preferable to standard laparoscopic nephrectomy because of shorter operating time and lower morbidity [[Lee & Clayman 2004](#)].

**Cyst hemorrhage and gross hematuria.** Episodes of cyst hemorrhage or of gross hematuria are usually self-limited and respond well to conservative management with bed rest, analgesics, and adequate hydration to prevent development of obstructing clots.

Rarely, episodes of bleeding are more severe with extensive subcapsular or retroperitoneal hematoma, significant drop in hematocrit, and hemodynamic instability. In such cases, individuals require hospitalization, transfusion, and investigation by CT or angiography. In cases of unusually severe or persistent hemorrhage, segmental arterial embolization can be successful. If not, surgery may be required to control bleeding.

Gross hematuria persisting more than one week or developing for the first time in an individual older than age 50 years requires thorough investigation.

**Nephrolithiasis.** Small uric acid stones can be missed on nephrotomography and are best detected by computed tomography (CT). CT should be obtained before and after the administration of contrast material to confirm the localization within the collecting system and to differentiate calculi from parenchymal calcifications.

Excretory urography detects precaliceal tubular ectasia in 15% of individuals with ADPKD.

The treatment of nephrolithiasis in individuals with ADPKD is the same as that for individuals without ADPKD.

- Potassium citrate is the treatment of choice in uric acid lithiasis, hypocitric calcium oxalate nephrolithiasis, and distal acidification defects [[Torres et al 1993](#)].
- Extracorporeal shock-wave lithotripsy and percutaneous nephrostolithotomy can be successful in individuals with ADPKD without excessive complications.

**Cyst infection.** If cyst infection is suspected, diagnostic imaging should be undertaken to assist in the diagnosis.

- CT and magnetic resonance imaging (MRI) are sensitive for detecting complicated cysts and provide anatomic definition, but the findings are not specific for infection.
- Nuclear imaging, especially indium-labeled white cell [scanning](#), is useful, but false-negative and false-positive results are possible.

In the appropriate clinical setting of fever, flank pain, and suggestive diagnostic imaging, cyst aspiration under ultrasound or CT guidance should be undertaken to culture the organism and assist in selection of antimicrobial therapy.



Cyst infection is often difficult to treat. It has a high treatment failure rate despite prolonged therapy with an antibiotic to which the organism is susceptible. Treatment failure results from the inability of certain antibiotics to penetrate the cyst epithelium successfully and achieve therapeutic concentrations within the cysts [Elzinga & Bennett 1996]. The epithelium that lines gradient cysts has functional and ultrastructural characteristics of the distal tubule epithelium. Penetration is via tight junctions, allowing only lipid-soluble agent access. Non-gradient cysts, which are more common, allow solute access via diffusion. However, kinetic studies indicate that water-soluble agents penetrate non-gradient cysts slowly and irregularly, resulting in unreliable drug concentrations within the cysts. Lipophilic agents have been shown to penetrate both gradient and non-gradient cysts equally and reliably and have a pKa that allows for favorable electrochemical gradients into acidic cyst fluids.

Therapeutic agents of choice include trimethoprim-sulfamethoxazole and fluoroquinolones. Chloramphenicol has shown therapeutic efficacy in otherwise refractory disease.

If fever persists after one to two weeks of appropriate antimicrobial therapy, percutaneous or surgical drainage of infected cysts should be undertaken. If fever recurs after discontinuation of antibiotics, complicating features, such as obstruction, perinephric abscess, or stones should be considered and treated appropriately. If complicating features are not identified, the course of previously effective therapy should be extended and several months may be required to completely eradicate the infection.

**Malignancy.** The diagnosis of **renal cell carcinoma** (RCC) in a polycystic kidney requires a high index of suspicion. Magnetic resonance imaging (MRI) with gadolinium enhancement is particularly helpful to detect atypical solid or cystic masses, tumor thrombi, and regional lymphadenopathy.

The diagnosis of **transitional cell carcinoma** in a polycystic kidney is equally challenging and usually requires retrograde pyelography.

**Renal failure.** Therapeutic interventions aimed at slowing the progression of renal failure in ADPKD include control of hypertension and hyperlipidemia, dietary [protein](#) restriction, control of acidosis, and prevention of hyperphosphatemia.

Animal data support the role of dietary [protein](#) restriction and careful control of hypertension in slowing the rate of renal failure in PKD [Qian et al 2001]. However, the Modification of Diet in Renal Disease (MDRD) trial showed no beneficial effect on renal function of strict — compared with standard — blood pressure control and only a slight (borderline significant) beneficial effect of a very low [protein](#) diet [Klahr et al 1995]. Since these interventions were introduced at a late state of the disease (GFR 13-55 mL/min per 1.73<sup>2</sup>), these results do not exclude a beneficial effect of interventions introduced at an earlier stage of the disease.

Actuarial data indicate that individuals with ADPKD do better on dialysis than individuals with renal failure from other causes. Females appear to do better than males. The reason for this improved outcome is unclear but may relate to better-maintained hemoglobin levels through higher endogenous erythropoietin production. Rarely, hemodialysis can be complicated by intradialytic hypotension if the inferior vena cava is compressed by a medially located renal cyst. Despite renal size, peritoneal dialysis can usually be performed in individuals with ADPKD, although these individuals are at increased risk for inguinal and umbilical hernias,



which require surgical repair.

**Polycystic liver disease.** Most individuals with polycystic liver disease have no symptoms and require no treatment [[Torres 1996](#)].

The treatment of symptomatic disease includes the avoidance of estrogens and the use of H2 blockers or proton pump inhibitors for symptomatic relief.

Severe symptoms may require percutaneous aspiration and sclerosis, laparoscopic fenestration, combined hepatic resection and cyst fenestration, or liver transplantation. Any of these interventions should be tailored to the individual.

Cyst aspiration and sclerosis with alcohol or minocycline is the treatment of choice for symptoms caused by one or a small number of [dominant](#) cysts. Before instillation of the sclerosing agent, a contrast medium is injected into the cyst to rule out communication with the bile ducts. The success rate of this procedure (70% after a single treatment and an additional 20% after repeated treatment) is inversely correlated with the size of the cyst(s).

Laparoscopic fenestration of hepatic cysts, a less commonly performed procedure, is complicated by transient ascites in 40% of individuals, and the results are often short-lived. Thus, laparoscopic cyst fenestration is indicated only for the treatment of disproportionally large cysts as an alternative to percutaneous sclerosis. Neither percutaneous sclerosis nor laparoscopic fenestration is helpful in individuals with large polycystic livers with many small- and medium-sized cysts. In most individuals, part of the liver is spared, allowing treatment by combined hepatic resection and cyst fenestration. Because the surgery and recovery can be difficult, with complications such as transient ascites and bile leaks and a perioperative mortality of 2.5%, it should be performed only in specialized centers. The surgery has good long-term results in individuals with severe polycystic liver disease and is often preferable to liver transplantation, which is reserved for those rare individuals with severely [affected](#) liver parenchyma and hepatic insufficiency [[Que et al 1995](#)].

## Intracranial aneurysms

**Ruptured or symptomatic intracranial aneurysm.** The mainstay of therapy is surgical clipping of the ruptured aneurysm at its neck.

## Asymptomatic aneurysms

- Those measuring 5.0 mm or smaller in diameter, diagnosed by presymptomatic [screening](#), can be observed and followed initially at yearly intervals. If the size increases, surgery is indicated.
- The management of aneurysms 6.0-9.0 mm in size remains controversial.
- Surgical intervention is usually indicated for unruptured aneurysms measuring larger than 10.0 mm in diameter.

For individuals with high surgical risk or with technically difficult-to-manage lesions, endovascular treatment with detachable platinum coils may be indicated. Endovascular treatment seems to be associated with fewer complications than clipping, but the long-term efficacy of this method is as yet unproven [[Pirson et al 2002](#)].

**Aortic dissection.** When the aortic root diameter reaches 55 mm to 60 mm,



replacement of the aorta is indicated.

## Surveillance

**Intracranial aneurysms.** Widespread [screening](#) is not cost effective or indicated because most intracranial aneurysms found by [screening](#) asymptomatic individuals are small, have a low risk of rupture, and require no treatment [[Gibbs et al 2004](#)].

Indications for [screening](#) in 20- to 50-year-old individuals with a good life expectancy include [family history](#) of intracranial aneurysms or subarachnoid hemorrhage, previous aneurysmal rupture, preparation for elective surgery with potential hemodynamic instability, high-risk occupations such as airplane pilots, significant anxiety on the part of the individual despite adequate risk information, and, possibly, [mutation](#) position in PKD1 [[Rossetti et al 2003](#)].

Magnetic resonance angiography is the diagnostic imaging modality of choice for presymptomatic [screening](#), as it is noninvasive and does not require intravenous contrast material. Because only one of 76 individuals with an initial negative study had a new intracranial aneurysm after a mean follow-up of 9.8 years, re-screening after an interval of ten years has been suggested as a reasonable approach [[Schrier et al 2004](#)].

## Agents/Circumstances to Avoid

- Long-term administration of nephrotoxic agents such as combination analgesics and NSAIDs
- Caffeine because it interferes with the breakdown of cAMP and hence may promote renal cyst growth
- Use of estrogens in individuals with severe polycystic liver disease
- Smoking

## Testing of Relatives at Risk

### ADPKD

- Testing of adult relatives at risk:
  - Allows those found to be [affected](#) to become better educated on the disease;
  - Permits early detection and treatment of complications and associated disorders;
  - Reassures those found to be [unaffected](#).
- Appropriate counseling prior to [screening](#), including a discussion of the possible impact on insurability and employability, is most important.
- At present, there is no indication for testing of asymptomatic children. This may change in the future if and when effective therapies are found.

**Aortic dissection.** Until more information becomes available, it is reasonable to [screen](#) first-degree adult relatives of individuals with thoracic aortic dissection using either echocardiography or MRI. If aortic root dilatation is found, yearly follow-up and strict blood pressure control with beta blockers should be recommended.

## Therapies Under Investigation

Significant advances in the understanding of the genetics of ADPKD and the



mechanisms of cyst growth have revealed likely targets for therapeutic intervention.

Of particular interest are recent studies that have shown that modulation of cAMP levels by targeting the vasopressin V2 receptor can dramatically inhibit cyst development in animal models of nephronophthisis, [autosomal recessive](#) polycystic kidney disease (ARPKD), and ADPKD [[Gattone et al 2003](#) , [Torres et al 2004](#) , [Wang et al 2005](#)]. A clinical trial with a vasopressin V2 receptor antagonist is currently in progress.

Octreotide, a long-acting form of somatostatin has been shown to slow the enlargement of polycystic kidneys in a small randomized, placebo-controlled, crossover study [[Ruggenti et al 2005](#)].

Antagonists of the epidermal growth factor receptor [[Sweeney et al 2000](#)] and rapamycin [[Tao et al 2005](#) , [Shillingford et al 2006](#) , [Wahl et al 2006](#)] have been effective in animal models of polycystic kidney disease.

Search [ClinicalTrials.gov](http://ClinicalTrials.gov) for access to information on clinical studies for a wide range of diseases and conditions.

## Genetic Counseling

*Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. To find a genetics or prenatal diagnosis clinic, see the [GeneTests Clinic Directory](#). —ED.*

### Mode of Inheritance

ADPKD is inherited in an [autosomal dominant](#) manner.

### Risk to Family Members

#### Parents of a **proband**

- Most [affected](#) individuals have one parent who has ADPKD.
- The incidence of *de novo* [mutations](#) is significant, occurring in about 10% of [affected](#) families.
- Recommendations for the evaluation of parents of a **proband** with an apparent *de novo* [mutation](#) include adequate [screening](#) by imaging methods, especially in the case of PKD2.

Note: The [family history](#) may also appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the [affected](#) parent.

#### Sibs of a **proband**

- The risk to sibs of the **proband** depends upon the genetic status of the parents.



- If a parent is [affected](#), the risk to sibs is 50%.
- When renal image analysis suggests that the parents are [unaffected](#) and the [disease-causing mutation](#) found in the [proband](#) cannot be detected in the [DNA](#) of the either parent, the disease in the [proband](#) is likely caused by a *de novo* [mutation](#) and the risk to sibs is small. Although no instances of [germline mosaicism](#) have been reported, it remains a possibility.

**Offspring of a [proband](#).** Every child of an individual with ADPKD has a 50% chance of inheriting the [mutation](#).

**Other family members of the [proband](#).** The risk to other family members depends upon the genetic status of the proband's parents. If a parent is found to be [affected](#) or to have a [disease-causing mutation](#), his or her relatives are at risk.

**Related kidney donor.** Relatives being considered as kidney donors need to be evaluated to determine if they have ADPKD. Evaluation usually consists of comprehensive renal image analysis by ultrasound, CT, and/or MRI. If a [disease-causing mutation](#) has been identified in the [affected](#) relative or if studies have established [linkage](#) in the family, [molecular genetic testing](#) is appropriate to establish the genetic status of the potential donor.

## Related Genetic Counseling Issues

**Testing of at-risk asymptomatic adults.** Testing of at-risk asymptomatic adults for ADPKD should first involve renal image analysis. [Molecular genetic testing](#) is also possible (as described), but this is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals.

Testing for the disease in the absence of definite symptoms of the disease is [predictive testing](#). Renal imaging should be considered as the first means to test for ADPKD. [Molecular genetic testing](#) should only be considered if the imaging results are equivocal or if a definite diagnosis in a young person (<30 years of age) is required, as for a potential renal transplant donor. At-risk asymptomatic adult family members may seek testing in order to make personal decisions. Others may have different motivations including simply the "need to know." Testing of asymptomatic at-risk adult family members usually involves pre-test interviews in which the motives for requesting the test, the individual's knowledge of ADPKD, and the possible impact of positive and negative test results are assessed. Those seeking testing should be counseled about possible problems that they may encounter with regard to health, life, and disability insurance coverage, employment discrimination, and changes in social and family interaction. Other issues to consider are implications for the at-risk status of other family members. [Informed consent](#) should be procured and records kept confidential. Individuals with a positive test result need arrangements for long term follow-up and evaluations.

**Testing of at-risk asymptomatic individuals during childhood.** In general, the consensus holds that whereas clinical monitoring for early disease presentations in individuals at risk for adult-onset disorder is important, such individuals should not have testing during childhood in the absence of symptoms. The principal arguments against testing asymptomatic individuals during childhood are that it removes their choice to know or not know this information, it raises the possibility of stigmatization within the family and in other social settings, and it could have serious educational and career implications [[Bloch & Hayden 1990](#) , [Harper & Clarke 1990](#)]. Individuals who become symptomatic during childhood



usually benefit from having a specific diagnosis established (See also the National Society of Genetic Counselors [resolution](#) on genetic testing of children and the American Society of Human Genetics and American College of Medical Genetics [points to consider](#) : ethical, legal, and psychosocial implications of genetic testing in children and adolescents).

**Considerations in families with an apparent *de novo* mutation.** When neither parent of a [proband](#) with an [autosomal dominant](#) condition has the [disease-causing mutation](#) or clinical evidence of the disorder, it is likely that the [proband](#) has a *de novo* [mutation](#). However, possible non-medical explanations including [alternate paternity](#) or undisclosed adoption could also be explored.

**Family planning.** The optimal time for determination of genetic risk and availability of [prenatal testing](#) is before pregnancy. Similarly, decisions about testing to determine the genetic status of at-risk asymptomatic family members are best made before pregnancy.

**DNA banking.** DNA banking is the storage of [DNA](#) (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of [genes](#), [mutations](#), and diseases will improve in the future, consideration should be given to banking [DNA](#) of [affected](#) individuals. [DNA banking](#) is particularly relevant in situations in which the [sensitivity](#) of currently available testing is less than 100%. See [DNA Banking](#) for a list of laboratories offering this service.

## Prenatal Testing

**Molecular genetic testing.** Prenatal diagnosis for pregnancies at increased risk is possible by analysis of [DNA](#) extracted from fetal cells obtained by amniocentesis usually performed at about 15-18 weeks' gestation or chorionic villus sampling (CVS) at about 10-12 weeks' gestation. The disease-causing [allele](#) of an [affected](#) family member must be identified or [linkage](#) established in the family before [prenatal testing](#) can be performed.

Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.

Requests for [prenatal testing](#) for adult-onset conditions such as ADPKD that do not affect intellect and have some treatment available are not common. The possible exception is in rare families in which a severely [affected](#) family member may present with perinatal lethality or with grossly enlarged kidneys during infancy. As such families are thought to be at high risk for a subsequent severely [affected](#) child, ultrasound monitoring for early evidence of renal enlargement is appropriate and [prenatal testing](#) may be considered in these families [[Zerres et al 1993](#)]. Differences in perspective may exist among medical professionals and in families regarding the use of [prenatal testing](#), particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Surveys of families with ADPKD suggest that only 4-8% of family members would terminate a pregnancy for ADPKD [[Sujansky et al 1990](#)]. Although most centers would consider decisions about [prenatal testing](#) to be the choice of the parents, careful discussion of these issues is appropriate.

**Preimplantation genetic diagnosis (PGD)** has been reported [[De Rycke et al 2005](#)] and may be available for families in which the [disease-causing mutation](#) has been identified in an [affected](#) family member or [linkage](#) established in the family in



a research or clinical laboratory. For laboratories offering PGD, see [Testing](#) .

## Molecular Genetics

*Information in the Molecular Genetics tables may differ from that in the text; tables may contain more recent information. —ED.*

### Molecular Genetics of Polycystic Kidney Disease, Autosomal Dominant

Gene Symbol	Chromosomal Locus	Protein Name
<i>PKD1</i>	16p13.3-p13.1	Polycystin-1
<i>PKD2</i>	4q21-q23	Polycystin-2

Data are compiled from the following standard references: Gene symbol from [HUGO](#); chromosomal locus, locus name, critical region, complementation group from [OMIM](#); protein name from [Swiss-Prot](#).

### OMIM Entries for Polycystic Kidney Disease, Autosomal Dominant

<a href="#">173900</a>	POLYCYSTIC KIDNEYS
<a href="#">173910</a>	POLYCYSTIC KIDNEY DISEASE 2; PKD2
<a href="#">601313</a>	POLYCYSTIC KIDNEY DISEASE 1; PKD1

### Genomic Databases for Polycystic Kidney Disease, Autosomal Dominant

Gene Symbol	Entrez Gene	HGMD	GeneCards	GDB	GenAtlas
<i>PKD1</i>	<a href="#">601313</a>	<a href="#">PKD1</a>	<a href="#">PKD1</a>	<a href="#">120293</a>	<a href="#">PKD1</a>
<i>PKD2</i>	<a href="#">173910</a>	<a href="#">PKD2</a>	<a href="#">PKD2</a>	<a href="#">118851</a>	<a href="#">PKD2</a>

For a description of the genomic databases listed, click [here](#).

## Molecular Genetic Pathogenesis

ADPKD is caused by [mutation](#) to the *PKD1* (~85% of individuals) or *PKD2* [genes](#) (~15% of individuals) with the probability of at least one further [locus](#) representing a small fraction of unlinked families [[Peters & Sandkuijl 1992](#) , [Daoust et al 1995](#)]. The *PKD1* [gene](#) was identified in 1994 [[European Polycystic Kidney Disease Consortium 1994](#)] and fully sequenced in 1995 [[Hughes et al 1995](#) , [International Polycystic Kidney Disease Consortium 1995](#)]. The *PKD2* [gene](#) was cloned in 1996 [[Mochizuki et al 1996](#)].

Polycystin-1 and polycystin-2 are thought to interact to form a functional complex.



Recent evidence indicates that, in common with many other PKD [proteins](#), polycystin-1 and polycystin-2 are localized on primary cilia and the polycystin complex may play a role in the detection of fluid flow within the tubule [[Pazour et al 2002](#) , [Yoder et al 2002](#) , [Nauli et al 2003](#)]. According to this hypothesis, flow within tubules of the normal kidney results in bending of cilia and activation of the polycystin flow sensor that results in a  $\text{Ca}^{2+}$  influx into the cell [[Praetorius & Spring 2001](#) , [Nauli et al 2003](#)]. Inactivation of the polycystin complex as a result of [mutations](#) in *PKD1* or *PKD2* (plus somatic events) results in altered  $\text{Ca}^{2+}$  homeostasis that may be associated with the multiple cellular changes (such as increased proliferation and apoptosis and altered polarity and secretory properties) that are characteristic of ADPKD cells [[Harris & Torres 2006](#) , [Torres & Harris 2006](#)].

Common to the vascular and cardiac lesions is the disruption of the connective tissue framework responsible for their mechanical properties. Abnormalities of the internal elastic lamina, which is responsible for most of the tensile strength of the wall of the intracranial arteries, cause intracranial aneurysms and dolichoectasias. Dissection of the thoracic aorta and cervicocephalic arteries is characterized by disruption of the normal myoelastic lamellar structure of the arterial wall. It seems likely that the *PKD1* and *PKD2* [mutations](#) are directly responsible for the vascular and cardiac manifestations of ADPKD, since polycystin-1 and polycystin-2 are strongly expressed in the medial myocytes of elastic and large distributive arteries, as well as in the cardiac myocytes and valvular myofibroblasts [[Griffin et al 1997](#) , [Torres et al 2001](#)].

### ***PKD1***

**Normal allelic variants:** *PKD1* encodes an approximately 14-kb transcript and is divided into 46 [exons](#) within 50 kb of [genomic DNA](#) [[Hughes et al 1995](#)]. The [genomic](#) region encoding *PKD1* has undergone a complex [duplication](#), such that several reiterated copies of the 5' three-quarters of the [gene](#) are present as [pseudogenes](#) elsewhere on [chromosome 16](#) [[European Polycystic Kidney Disease Consortium 1994](#)]. The similarity of these [pseudogenes](#) to *PKD1* has complicated [molecular genetic testing](#) at this [locus](#). Several alternatively spliced forms of *PKD1* have also been described, but the functional significance of any of these is not known [[Hughes et al 1995](#) , [International Polycystic Kidney Disease Consortium 1995](#)].

*PKD1* orthologs have been sequenced from a wide range of mammalian species and from amphibians and [fish](#). No true orthologs are found in more primitive species, but homologous [proteins](#) in *C. elegans* and sea urchins have provided insights into the function of polycystin-1-like [proteins](#) [[Moy et al 1996](#) , [Barr & Sternberg 1999](#) , [Mengerink et al 2002](#)].

**Pathologic allelic variants:** *PKD1* is characterized by extreme allelic variability, with most [mutations](#) unique to a single family [[Rossetti et al 2001](#) ; [Rossetti, Chauveau et al 2002](#) ; Rossetti et al, manuscript in preparation]. The [mutations](#) are spread throughout the [gene](#) and the majority are predicted to truncate the [product](#). The pattern is consistent with the [mutations](#) inactivating the [allele](#) and it has been suggested that a somatic [mutation](#) disrupting the normal [allele](#) is required for cyst development [[Qian et al 1996](#)]. About 270 different *PKD1* [mutations](#) have been described (see HGMD, [Genomic Databases Table above](#)).

**Normal gene product:** The *PKD1* [gene product](#), polycystin, is a 4303 amino-acid (aa) [protein](#) with a calculated molecular mass of 460 kd [[Hughes et al 1995](#) ,



[International Polycystic Kidney Disease Consortium 1995](#) , [Sandford et al 1997](#)]. The [protein](#) is membrane-associated with a large extracellular region and short cytoplasmic tail. The extracellular area contains several characterized [domains](#) that are generally involved in interactions with [proteins](#) or carbohydrates. The function of the [protein](#) is not known. It may be a receptor, although the ligand has not been identified [[Ong & Harris 2005](#)].

Polycystin-1 is expressed in the epithelia of maturing tubules in the kidney and epithelial cells in many other organs, with the highest expression in the embryo and down-regulation in the adult. Expression is also found in smooth, skeletal, and cardiac muscle, suggesting that polycystin has a direct role in many of the extrarenal manifestations of the disease.

**Abnormal gene product:** The wide array of truncating [mutations](#) in *PKD1* that cause ADPKD suggests that they inactivate the [gene](#) with no functional [protein](#) produced. However, evidence of genotype/phenotype correlations associated with [mutation](#) position and the fact that polycystin-1 may be cleaved into more than one [protein product](#) indicate that all [mutations](#) may not simply inactivate all [products](#) [[Qian et al 2002](#) ; [Rossetti, Burton et al 2002](#) ; [Rossetti et al 2003](#) ; [Chauvet et al 2004](#) , [Low et al 2006](#)]. Recent evidence indicates that a reduction in the level of polycystin-1 [protein](#) may be sufficient for cyst development and that cyst expansion may be a complex process [[Lantinga-van Leeuwen et al 2004](#) , [Nishio et al 2005](#) , [Jiang et al 2006](#)].

## **PKD2**

**Normal allelic variants:** *PKD2* encodes an approximately 3-kb [open reading frame](#) that is encoded by 15 [exons](#) in a [genomic](#) area of approximately 70 kb [[Hayashi et al 1997](#)].

*PKD2* orthologs or [homologs](#) have been characterized in many mammalian species, frog, [fish](#), and many invertebrates including *C. elegans* and *Drosophila*. Polycystin-2-like [proteins](#) in these species have a range of roles from influencing mating behavior to defects in sperm motility [[Barr & Sternberg 1999](#) , [Gao et al 2003](#)].

**Pathologic allelic variants:** *PKD2* is characterized by extreme allelic variability, with most [mutations](#) unique to a single family [[Veldhuisen et al 1997](#)]. As in *PKD1*, the [mutations](#) are spread throughout the [gene](#) and the majority are predicted to truncate the [protein](#), consistent with inactivation of the [allele](#). Approximately 75 different *PKD2* [mutations](#) have been described (see HGMD, [Genomic Databases Table above](#)).

**Normal gene product:** Polycystin-2 is predicted to have six transmembrane [domains](#) with cytoplasmic N- and C-termini. It shares a region of homology with polycystin-1 in the transmembrane region and also has sequence similarity to TRP and voltage-activated channel subunits. Polycystin-2 acts as a Ca<sup>2+</sup> permeable cation channel and the basic defect in ADPKD may be in aberrant regulation of intracellular Ca<sup>2+</sup> [[Hanaoka et al 2000](#) , [Gonzalez-Perrett et al 2001](#) , [Vassilev et al 2001](#) , [Koulen et al 2002](#)]. A recent focus has been the role of polycystin-2 on the primary cilia and its function in the influx of Ca<sup>2+</sup> associated with flow, although it may also be associated with intracellular Ca<sup>2+</sup> stores in the ER. Polycystin-2 expression is similar to that of polycystin-1, but it continues at a more consistent level in the adult.



**Abnormal gene product:** The wide array of truncating [mutations](#) in *PKD2* suggests that they inactivate the [gene](#) with no functional [protein](#) produced.

## Resources

*GeneReviews provides information about selected national organizations and resources for the benefit of the reader. GeneReviews is not responsible for information provided by other organizations. -ED.*

- **National Library of Medicine Genetics Home Reference**  
[Polycystic kidney disease](#)

- **NCBI Genes and Disease**  
[APKD](#)

- **The PKD Charity**  
PO Box 141  
Bishop Auckland  
County Durham DL14 6ZD  
United Kingdom  
**Phone:** 01388 665004  
**Email:** [support@pkdcharity.org.uk](mailto:support@pkdcharity.org.uk)  
[www.pkdcharity.co.uk](http://www.pkdcharity.co.uk)

- **PKD Foundation**  
9221 Ward Parkway Suite 400  
Kansas City MO 64114-3367  
**Phone:** 800-PKD-CURE  
**Fax:** 816-931-8655  
**Email:** [pkdcure@pkdcure.org](mailto:pkdcure@pkdcure.org)  
[www.pkdcure.org](http://www.pkdcure.org)

- **The Kidney Foundation of Canada**  
700-15 Gervais Drive  
Toronto M3C 1Y8  
Canada  
**Phone:** 800-387-4474; 416-445-0373  
**Fax:** 416-445-7440  
**Email:** [centralontario@kidneycob.on.ca](mailto:centralontario@kidneycob.on.ca)  
[www.kidney.on.ca](http://www.kidney.on.ca)

- **National Kidney Foundation**  
30 East 33rd Street Suite 1100  
New York NY 10016  
**Phone:** 800-622-9010; 212-889-2210  
**Fax:** 212-689-9261  
**Email:** [info@kidney.org](mailto:info@kidney.org)  
[www.kidney.org](http://www.kidney.org)

- **Teaching Case-Genetic Tools**  
*Cases designed for teaching genetics in the primary care setting.*  
[Case 33. Renal Failure in a 38-Year-Old Woman](#)



 [Resources Printable Copy](#)

## References

### PubMed

#### Published Statements and Policies Regarding Genetic Testing

- American Society of Human Genetics and American College of Medical Genetics (1995) [Points to consider](#) : ethical, legal, and psychosocial implications of genetic testing in children and adolescents
- National Society of Genetic Counselors (1995) [Resolution](#) on prenatal and childhood testing for adult-onset disorders

#### Literature Cited

- Adeva M, El-Youssef M, Rossetti S, Kamath PS, Kubly V, Consugar MB, Milliner DM, King BF, Torres VE, Harris PC (2006) Clinical and molecular characterization defines a broadened spectrum of [autosomal recessive](#) polycystic kidney disease (ARPKD). *Medicine (Baltimore)* 85:1-21 [[Medline](#)]
- Ariyurek Y, Lantinga-van Leeuwen I, Spruit L, Ravine D, Breuning MH, Peters DJ (2004) Large [deletions](#) in the polycystic kidney disease 1 (PKD1) [gene](#). *Hum Mutat* 23:99 [[Medline](#)]
- Barr MM and Sternberg PW (1999) A polycystic kidney-disease [gene](#) homologue required for male mating behaviour in *C. elegans*. *Nature* 401:386-9 [[Medline](#)]
- Belz MM, Fick-Brosnahan GM, Hughes RL, Rubinstein D, Chapman AB, Johnson AM, McFann KK, Kaehny WD, Gabow PA (2003) Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease. *Kidney Int* 63:1824-30 [[Medline](#)]
- Bloch M and Hayden MR (1990) Opinion: [predictive testing](#) for Huntington disease in childhood: challenges and implications. *Am J Hum Genet* 46:1-4 [[Medline](#)]
- Chapman AB, Johnson A, Gabow PA, Schrier RW (1990) The renin-angiotensin-aldosterone system and [autosomal dominant](#) polycystic kidney disease. *N Engl J Med* 323:1091-6 [[Medline](#)]
- Chapman AB, Johnson AM, Gabow PA (1994) Pregnancy outcome and its relationship to progression of renal failure in [autosomal dominant](#) polycystic kidney disease. *J Am Soc Nephrol* 5:1178-85 [[Medline](#)]
- Chapuis O, Sockeel P, Pallas G, Pons F, Jancovici R (2004) Thoracoscopic renal denervation for intractable [autosomal dominant](#) polycystic kidney disease-related pain. *Am J Kidney Dis* 43:161-3 [[Medline](#)]



- Chauvet V, Tian X, Husson H, Grimm DH, Wang T, Hiesberger T, Igarashi P, Bennett AM, Ibraghimov-Beskrovnaya O, Somlo S, Caplan MJ (2004) Mechanical stimuli induce cleavage and nuclear [translocation](#) of the polycystin-1 C terminus. *J Clin Invest* 114:1433-43 [[Medline](#)]
- Daoust MC, Reynolds DM, Bichet DG, Somlo S (1995) Evidence for a third genetic [locus](#) for [autosomal dominant](#) polycystic kidney disease. *Genomics* 25:733-6 [[Medline](#)]
- Davila S, Furu L, Gharavi AG, Tian X, Onoe T, Qian Q, Li A, Cai Y, Kamath PS, King BF, Azurmendi PJ, Tahvanainen P, Kaariainen H, Hockerstedt K, Devuyst O, Pirson Y, Martin RS, Lifton RP, Tahvanainen E, Torres VE, Somlo S (2004) [Mutations](#) in SEC63 cause [autosomal dominant](#) polycystic liver disease. *Nat Genet* 36:575-7 [[Medline](#)]
- De Rycke M, Georgiou I, Sermon K, Lissens W, Henderix P, Joris H, Platteau P, Van Steirteghem A, Liebaers I (2005) PGD for [autosomal dominant](#) polycystic kidney disease type 1. *Mol Hum Reprod* 11:65-71 [[Medline](#)]
- Drenth JP, te Morsche RH, Smink R, Bonifacino JS, Jansen JB (2003) [Germline mutations](#) in PRKCSH are associated with [autosomal dominant](#) polycystic liver disease. *Nat Genet* 33:345-7 [[Medline](#)]
- Dunn MD, Portis AJ, Elbahnasy AM, Shalhav AL, Rothstein M, McDougall EM, Clayman RV (2000) Laparoscopic nephrectomy in patients with end-stage renal disease and [autosomal dominant](#) polycystic kidney disease. *Am J Kidney Dis* 35:720-5 [[Medline](#)]
- Ecker T and Schrier RW (2001) Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. *J Am Soc Nephrol* 12:194-200 [[Medline](#)]
- Elzinga LW and Bennett WM (1996) Miscellaneous renal and systemic complications of [autosomal dominant](#) polycystic kidney disease including infection. In: Watson ML, Torres VE (eds) Polycystic Kidney Disease. Oxford Medical Publications, pp 483-99
- Elzinga LW, Barry JM, Torres VE, Zincke H, Wahner HW, Swan S, Bennett WM (1992) Cyst decompression surgery for [autosomal dominant](#) polycystic kidney disease. *J Am Soc Nephrol* 2:1219-26 [[Medline](#)]
- European Polycystic Kidney Disease Consortium (1994) The polycystic kidney disease 1 [gene](#) encodes a 14 kb transcript and lies within a duplicated region on [chromosome](#) 16. *Cell* 77:881-94. [[Medline](#)]
- Fain PR, McFann KK, Taylor MR, Tison M, Johnson AM, Reed B, Schrier RW (2005) Modifier [genes](#) play a significant role in the [phenotypic](#) expression of PKD1. *Kidney Int* 67:1256-67 [[Medline](#)]
- Gabow P (1996) Definition and natural history of [autosomal dominant](#) polycystic kidney disease. In: Watson ML, Torres VE (eds) Polycystic Kidney Disease. Oxford University Press, Oxford, pp 333-55
- Gaines PA and Sampson MA (1989) The prevalence and characterization of



simple hepatic cysts by ultrasound examination. *Br J Radiol* 62:335-7  
[[Medline](#)]

- Gao Z, Ruden DM, Lu X (2003) PKD2 cation channel is required for directional sperm movement and male fertility. *Curr Biol* 13:2175-8 [[Medline](#)]
- Gattone VH 2nd, Wang X, Harris PC, Torres VE (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. *Nat Med* 9:1323-6 [[Medline](#)]
- Geberth S, Ritz E, Zeier M, Stier E (1995) [Anticipation](#) of age at renal death in [autosomal dominant](#) polycystic kidney disease (ADPKD)? *Nephrol Dial Transplant* 10:1603-6 [[Medline](#)]
- Gibbs GF, Huston J 3rd, Qian Q, Kubly V, Harris PC, Brown RD Jr, Torres VE (2004) Follow-up of intracranial aneurysms in autosomal-dominant polycystic kidney disease. *Kidney Int* 65:1621-7 [[Medline](#)]
- Gonzalez-Perrett S, Kim K, et al (2001) Polycystin-2, the [protein](#) mutated in [autosomal dominant](#) polycystic kidney disease (ADPKD), is a Ca<sup>2+</sup>-permeable non-selective cation channel. *Proc Natl Acad Sci USA* 98:1182 [[Medline](#)]
- Griffin MD, Torres VE, Grande JP, Kumar R (1997) Vascular expression of polycystin. *J Am Soc Nephrol* 8:616-26 [[Medline](#)]
- Hanaoka K, Qian F, Boletta A, Bhunia AK, Piontek K, Tsiokas L, Sukhatme VP, Guggino WB, Germino GG (2000) Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. *Nature* 408:990-4 [[Medline](#)]
- Harper PS and Clarke A (1990) Should we test children for "adult" genetic diseases? *Lancet* 335:1205-6 [[Medline](#)]
- Harris PC and Torres VE (2006) Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy. *Curr Opin Nephrol Hypertens* 15:456-63 [[Medline](#)]
- Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggart-Malik AK, San Millan JL, Torra R, Breuning M, Ravine D (1999) Comparison of [phenotypes](#) of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. *Lancet* 353:103-7 [[Medline](#)]
- Hayashi T, Mochizuki T, Reynolds DM, Wu G, Cai Y, Somlo S (1997) Characterization of the [exon](#) structure of the polycystic kidney disease 2 [gene](#) (PKD2). *Genomics* 44:131-6 [[Medline](#)]
- Hughes J, Ward CJ, Peral B, Aspinwall R, Clark K, San Millan JL, Gamble V, Harris PC (1995) The polycystic kidney disease 1 (PKD1) [gene](#) encodes a novel [protein](#) with multiple cell recognition [domains](#). *Nat Genet* 10:151-60 [[Medline](#)]
- Iglesias CG, Torres VE, Offord KP, Holley KE, Beard CM, Kurland LT (1983) Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980. *Am J Kidney Dis* 2:630-9 [[Medline](#)]



- Inagawa T (2001) Trends in incidence and case fatality rates of aneurysmal subarachnoid hemorrhage in Izumo City, Japan, between 1980-1989 and 1990-1998. *Stroke* 32:1499-507 [[Medline](#)]
- International Polycystic Kidney Disease Consortium (1995) Polycystic kidney disease: the complete structure of the PKD1 [gene](#) and its [protein](#). *Cell* 81:289-98 [[Medline](#)]
- International Study of Unruptured Intracranial Aneurysms Investigators (1998) Unruptured intracranial aneurysms--risk of rupture and risks of surgical intervention. *N Engl J Med* 339:1725-33 [[Medline](#)]
- Jiang ST, Chiou YY, Wang E, Lin HK, Lin YT, Chi YC, Wang CK, Tang MJ, Li H (2006) Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1. *Am J Pathol* 168:205-20 [[Medline](#)]
- Keith DS, Torres VE, King BF, Zincki H, Farrow GM (1994) Renal cell carcinoma in [autosomal dominant](#) polycystic kidney disease. *J Am Soc Nephrol* 4:1661-9 [[Medline](#)]
- Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, Steinman TI, Wang SR, Yamamoto ME (1995) Dietary [protein](#) restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. *J Am Soc Nephrol* 5:2037-47 [[Medline](#)]
- Koulen P, Cai Y, Geng L, Maeda Y, Nishimura S, Witzgall R, Ehrlich BE, Somlo S (2002) Polycystin-2 is an intracellular calcium release channel. *Nat Cell Biol* 4:191-7 [[Medline](#)]
- Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, Leonhard WN, van de Wal A, Ward CJ, Verbeek S, Deruiter MC, Breuning MH, de Heer E, Peters DJ (2004) Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. *Hum Mol Genet* 13:3069-77 [[Medline](#)]
- Lee DI and Clayman RV (2004) Hand-assisted laparoscopic nephrectomy in [autosomal dominant](#) polycystic kidney disease. *J Endourol* 18:379-82 [[Medline](#)]
- Li A, Davila S, Furu L, Qian Q, Tian X, Kamath PS, King BF, Torres VE, Somlo S (2003) [Mutations](#) in PRKCSH cause [isolated autosomal dominant](#) polycystic liver disease. *Am J Hum Genet* 72:691-703 [[Medline](#)]
- Low SH, Vasanth S, Larson CH, Mukherjee S, Sharma N, Kinter MT, Kane ME, Obara T, Weimbs T (2006) Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. *Dev Cell* 10:57-69 [[Medline](#)]
- Lu W, Peissel B, Babakhanlou H, Pavlova A, Geng L, Fan X, Larson C, Brent G, Zhou J (1997) Perinatal lethality with kidney and pancreas defects in mice with a targeted Pkd1 [mutation](#). *Nat Genet* 17:179-81 [[Medline](#)]
- Magistroni R, He N, Wang K, Andrew R, Johnson A, Gabow P, Dicks E, Parfrey



- P, Torra R, San-Millan JL, Coto E, Van Dijk M, Breuning M, Peters D, Bogdanova N, Ligabue G, Albertazzi A, Hateboer N, Demetriou K, Pierides A, Deltas C, St George-Hyslop P, Ravine D, Pei Y (2003) Genotype-renal function correlation in type 2 [autosomal dominant](#) polycystic kidney disease. *J Am Soc Nephrol* 14:1164-74 [[Medline](#)]
- Martinez-Vea A, Bardaj A, Gutierrez C, Garca C, Peralta C, Marcos L, Oliver JA (2004) Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: a prehypertensive state. *Am J Kidney Dis* 44:216-23 [[Medline](#)]
  - Mengerink KJ, Moy GW, Vacquier VD (2002) suREJ3, a polycystin-1 [protein](#), is cleaved at the GPS [domain](#) and localizes to the acrosomal region of sea urchin sperm. *J Biol Chem* 277:943-8 [[Medline](#)]
  - Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, Reynolds DM, Cai Y, Gabow PA, Pierides A, Kimberling WJ, Breuning MH, Deltas CC, Peters DJ, Somlo S (1996) PKD2, a [gene](#) for polycystic kidney disease that encodes an integral membrane [protein](#). *Science* 272:1339-42 [[Medline](#)]
  - Moy GW, Mendoza LM, Schulz JR, Swanson WJ, Glabe CG, Vacquier VD (1996) The sea urchin sperm receptor for egg jelly is a modular [protein](#) with extensive homology to the human polycystic kidney disease [protein](#), PKD1. *J Cell Biol* 133:809-17 [[Medline](#)]
  - Naitoh H, Shoji H, Ishikawa I, Watanabe R, Furuta Y, Tomozawa S, Igarashi H, Shinozaki S, Katsura H, Onozato R, Kudoh M (2005) Intraductal papillary mucinous tumor of the pancreas associated with [autosomal dominant](#) polycystic kidney disease. *J Gastrointest Surg* 9:843-5 [[Medline](#)]
  - Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, Elia AE, Lu W, Brown EM, Quinn SJ, Ingber DE, Zhou J (2003) Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. *Nat Genet* 33:129-37 [[Medline](#)]
  - Nicolau C, Torra R, Badenas C, Vilana R, Bianchi L, Gilabert R, Darnell A, Bru C (1999) [Autosomal dominant](#) polycystic kidney disease types 1 and 2: assessment of US [sensitivity](#) for diagnosis. *Radiology* 213:273-6 [[Medline](#)]
  - Nishio S, Hatano M, Nagata M, Horie S, Koike T, Tokuhisa T, Mochizuki T (2005) Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. *J Clin Invest* 115:910-8 [[Medline](#)]
  - Oflaz H, Alisir S, Buyukaydin B, Kocaman O, Turgut F, Namli S, Pamukcu B, Oncul A, Ecder T (2005) Biventricular diastolic dysfunction in patients with autosomal-dominant polycystic kidney disease. *Kidney Int* 68:2244-9 [[Medline](#)]
  - Ong AC and Harris PC (2005) Molecular pathogenesis of ADPKD: the polycystin complex gets complex. *Kidney Int* 67:1234-47 [[Medline](#)]
  - Paterson AD, Magistroni R, He N, Wang K, Johnson A, Fain PR, Dicks E,



- Parfrey P, St George-Hyslop P, Pei Y (2005) Progressive loss of renal function is an age-dependent heritable trait in type 1 [autosomal dominant](#) polycystic kidney disease. *J Am Soc Nephrol* 16:755-62 [[Medline](#)]
- Paterson AD, Wang KR, Lupea D, St George-Hyslop P, Pei Y (2002) Recurrent fetal loss associated with bilineal inheritance of type 1 [autosomal dominant](#) polycystic kidney disease. *Am J Kidney Dis* 40:16-20 [[Medline](#)]
  - Pazour GJ, San Agustin JT, Follit JA, Rosenbaum JL, Witman GB (2002) Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. *Curr Biol* 12:R378-80 [[Medline](#)]
  - Pei Y, Paterson AD, Wang KR, He N, Hefferton D, Watnick T, Germino GG, Parfrey P, Somlo S, St George-Hyslop P (2001) Bilineal disease and trans-heterozygotes in [autosomal dominant](#) polycystic kidney disease. *Am J Hum Genet* 68:355-63 [[Medline](#)]
  - Persu A, Duyme M, Pirson Y, Lens XM, Messiaen T, Breuning MH, Chauveau D, Levy M, Grunfeld JP, Devuyst O (2004) Comparison between siblings and twins supports a role for modifier [genes](#) in ADPKD. *Kidney Int* 66:2132-6 [[Medline](#)]
  - Peters DJM, Sandkuijl LA (1992) Genetic heterogeneity of polycystic kidney disease in Europe. In: Breuning MH, Devoto M, Romeo G (eds) *Contributions to Nephrology: Polycystic Kidney Disease*, v 97. Karger, Basel, pp 128-39
  - Pirson Y, Chauveau D, Torres V (2002) Management of cerebral aneurysms in [autosomal dominant](#) polycystic kidney disease. *J Am Soc Nephrol* 13:269-76 [[Medline](#)]
  - Praetorius HA and Spring KR (2001) Bending the MDCK cell primary cilium increases intracellular calcium. *J Membr Biol* 184:71-9 [[Medline](#)]
  - Qian F, Boletta A, Bhunia AK, Xu H, Liu L, Ahrabi AK, Watnick TJ, Zhou F, Germino GG (2002) Cleavage of polycystin-1 requires the receptor for egg jelly [domain](#) and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated [mutations](#). *Proc Natl Acad Sci U S A* 99:16981-6 [[Medline](#)]
  - Qian F, Watnick TJ, Onuchic LF, Germino GG (1996) The molecular basis of focal cyst formation in human [autosomal dominant](#) polycystic kidney disease type I. *Cell* 87:979-87 [[Medline](#)]
  - Qian Q, Harris PC, Torres VE (2001) Treatment prospects for autosomal-dominant polycystic kidney disease. *Kidney Int* 59:2005-22 [[Medline](#)]
  - Qian Q, Li A, King BF, Kamath PS, Lager DJ, Huston J 3rd, Shub C, Davila S, Somlo S, Torres VE (2003) Clinical profile of [autosomal dominant](#) polycystic liver disease. *Hepatology* 37:164-71 [[Medline](#)]
  - Que F, Nagorney DM, Gross JB Jr, Torres VE (1995) Liver resection and cyst fenestration in the treatment of severe polycystic liver disease. *Gastroenterology* 108:487-94 [[Medline](#)]



- Ravine D, Gibson RN, Donlan J, Sheffield LJ (1993) An ultrasound renal cyst prevalence survey: [specificity](#) data for inherited renal cystic diseases. *Am J Kidney Dis* 22:803-7 [[Medline](#)]
- Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM (1994) Evaluation of ultrasonographic diagnostic criteria for [autosomal dominant](#) polycystic kidney disease 1. *Lancet* 343:824-7 [[Medline](#)]
- Reynolds DM, Falk CT, Li A, King BF, Kamath PS, Huston J 3rd, Shub C, Iglesias DM, Martin RS, Pirson Y, Torres VE, Somlo S (2000) Identification of a [locus](#) for [autosomal dominant](#) polycystic liver disease, on [chromosome](#) 19p13.2-13.1. *Am J Hum Genet* 67:1598-604 [[Medline](#)]
- Rossetti S, Burton S, Strmecki L, Pond GR, San Millan JL, Zerres K, Barratt TM, Ozen S, Torres VE, Bergstralh EJ, Winearls CG, Harris PC (2002) The position of the polycystic kidney disease 1 (PKD1) [gene mutation](#) correlates with the severity of renal disease. *J Am Soc Nephrol* 13:1230-7 [[Medline](#)]
- Rossetti S, Chauveau D, Kubly V, Slezak JM, Saggar-Malik AK, Pei Y, Ong AC, Stewart F, Watson ML, Bergstralh EJ, Winearls CG, Torres VE, Harris PC (2003) Association of [mutation](#) position in polycystic kidney disease 1 (PKD1) [gene](#) and development of a vascular [phenotype](#). *Lancet* 361:2196-201 [[Medline](#)]
- Rossetti S, Chauveau D, Walker D, Saggar-Malik A, Winearls CG, Torres VE, Harris PC (2002) A complete [mutation screen](#) of the ADPKD [genes](#) by DHPLC. *Kidney Int* 61:1588-99 [[Medline](#)]
- Rossetti S, Strmecki L, Gamble V, Burton S, Sneddon V, Peral B, Roy S, Bakkaloglu A, Komel R, Winearls CG, Harris PC (2001) [Mutation](#) analysis of the entire PKD1 gene: genetic and diagnostic implications. *Am J Hum Genet* 68:46-63 [[Medline](#)]
- Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, Remuzzi G, Epstein FH (2005) Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. *Kidney Int* 68:206-16 [[Medline](#)]
- Sampson JR, Maheshwar MM, Aspinwall R, Thompson P, Cheadle JP, Ravine D, Roy S, Haan E, Bernstein J, Harris PC (1997) Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 [gene](#). *Am J Hum Genet* 61:843-51 [[Medline](#)]
- Sandford R, Sgotto B, Aparicio S, Brenner S, Vaudin M, Wilson RK, Chisoe S, Pepin K, Bateman A, Chothia C, Hughes J, Harris P (1997) Comparative analysis of the polycystic kidney disease 1 (PKD1) [gene](#) reveals an integral membrane glycoprotein with multiple evolutionary conserved [domains](#). *Hum Mol Genet* 6:1483-9 [[Medline](#)]
- Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS (2005) The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. *Ann Intern Med* 142:342-51 [[Medline](#)]



- Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison L (2002) Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. *J Am Soc Nephrol* 13:1733-9 [[Medline](#)]
- Schrier RW, Belz MM, Johnson AM, Kaehny WD, Hughes RL, Rubinstein D, Gabow PA (2004) Repeat imaging for intracranial aneurysms in patients with [autosomal dominant](#) polycystic kidney disease with initially negative studies: a prospective ten-year follow-up. *J Am Soc Nephrol* 15:1023-8 [[Medline](#)]
- Segura JW, King BF, et al (1996) Chronic pain and its medical and surgical management in renal cystic diseases. In: Watson ML, Torres VE (eds) *Polycystic Kidney Disease*. Oxford Medical Publications, Oxford, pp 462-80
- Sharp CK, Bergman SM, Stockwin JM, Robbin ML, Galliani C, Guay-Woodford LM (1997) Dominantly transmitted glomerulocystic kidney disease: a distinct genetic entity. *J Am Soc Nephrol* 8:77-84 [[Medline](#)]
- Sherstha R, McKinley C, Russ P, Scherzinger A, Bronner T, Showalter R, Everson GT, Sherstha, R, McKinley, C, Russ, P, Scherzinger, A, Bronner, T, Showalter, R, Everson, G T (1997) Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with [autosomal dominant](#) polycystic kidney disease. *Hepatology* 26:1282-6 [[Medline](#)]
- Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. *Proc Natl Acad Sci U S A* 103:5466-71 [[Medline](#)]
- Sujansky E, Kreutzer SB, Johnson AM, Lezotte DC, Schrier RW, Gabow PA, Sujansky, E, Kreutzer, S B, Johnson, A M, Lezotte, D C, Schrier, R W, Gabow, P A (1990) Attitudes of at-risk and [affected](#) individuals regarding [presymptomatic testing](#) for [autosomal dominant](#) polycystic kidney disease. *Am J Med Genet* 35:510-5 [[Medline](#)]
- Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED (2000) Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. *Kidney Int* 57:33-40 [[Medline](#)]
- Tahvanainen P, Tahvanainen E, Reijonen H, Halme L, Kaariainen H, Hockerstedt K (2003) Polycystic liver disease is genetically heterogeneous: clinical and [linkage](#) studies in eight Finnish families. *J Hepatol* 38:39-43 [[Medline](#)]
- Tao Y, Kim J, Schrier RW, Edelstein CL (2005) Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. *J Am Soc Nephrol* 16:46-51 [[Medline](#)]
- Telenti A, Torres VE, Gross JB Jr, Van Scoy RE, Brown ML, Hattery RR (1990) Hepatic cyst infection in [autosomal dominant](#) polycystic kidney disease. *Mayo*



*Clin Proc* 65:933-42 [[Medline](#)]

- Torres V (1996) Polycystic liver disease. In: Watson MT, Torres VE (eds) Polycystic Kidney Disease. Oxford Medical Publications, Oxford, pp 500-29
- Torres VE, Keith DS, Offord KP, Kon SP, Wilson DM (1994) Renal ammonia in [autosomal dominant](#) polycystic kidney disease. *Kidney Int* 45:1745-53 [[Medline](#)]
- Torres VE, Rastogi S, King BF, Stanson AW, Gross JB Jr, Nogorney DM (1994) Hepatic venous outflow obstruction in [autosomal dominant](#) polycystic kidney disease. *J Am Soc Nephrol* 5:1186-92 [[Medline](#)]
- Torres VE, Cai Y, Chen X, Wu GQ, Geng L, Cleghorn KA, Johnson CM, Somlo S (2001) Vascular expression of polycystin-2. *J Am Soc Nephrol* 12:1-9 [[Medline](#)]
- Torres VE and Harris PC (2006) Mechanisms of disease: [autosomal dominant](#) and [recessive](#) polycystic kidney disease. *Nat Clin Prac Nephrol* 2:40-55
- Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd (2004) Effective treatment of an orthologous model of [autosomal dominant](#) polycystic kidney disease. *Nat Med* 10:363-4 [[Medline](#)]
- Torres VE, Wilson DM, Hattery RR, Segura JW (1993) Renal stone disease in [autosomal dominant](#) polycystic kidney disease. *Am J Kidney Dis* 22:513-9 [[Medline](#)]
- Torres VE, Wilson DM, Burnett JC Jr, Johnson CM, Offord KP (1991) Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. *Mayo Clin Proc* 66:1010-7 [[Medline](#)]
- Ubara Y, Katori H, Tagami T, Tanaka S, Yokota M, Matsushita Y, Takemoto F, Imai T, Inoue S, Kuzuhara K, Hara S, Yamada A (1999) Transcatheter renal arterial embolization therapy on a patient with polycystic kidney disease on hemodialysis. *Am J Kidney Dis* 34:926-31 [[Medline](#)]
- van Dijk MA, Breuning MH, Duiser R, van Es LA, Westendorp RG (2003) No effect of enalapril on progression in [autosomal dominant](#) polycystic kidney disease. *Nephrol Dial Transplant* 18:2314-20 [[Medline](#)]
- Vassilev PM, Guo L, Chen XZ, Segal Y, Peng JB, Basora N, Babakhanlou H, Cruger G, Kanazirska M, Ye Cp, Brown EM, Hediger MA, Zhou J (2001) Polycystin-2 is a novel cation channel implicated in defective intracellular Ca(2+) homeostasis in polycystic kidney disease. *Biochem Biophys Res Commun* 282:341-50 [[Medline](#)]
- Veldhuisen B, Saris JJ, de Haij S, Hayashi T, Reynolds DM, Mochizuki T, Elles R, Fossdal R, Bogdanova N, van Dijk MA, Coto E, Ravine D, Norby S, Verellen-Dumoulin C, Breuning MH, Somlo S, Peters DJ (1997) A spectrum of [mutations](#) in the second [gene](#) for [autosomal dominant](#) polycystic kidney disease (PKD2). *Am J Hum Genet* 61:547-55 [[Medline](#)]



- Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP (2006) Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with [autosomal dominant](#) polycystic kidney disease (ADPKD). *Nephrol Dial Transplant* 21:598-604 [[Medline](#)]
- Wang X, Gattone V 2nd, Harris PC, Torres VE (2005) Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. *J Am Soc Nephrol* 16:846-51 [[Medline](#)]
- Wong H, Vivian L, Weiler G, Filler G (2004) Patients with [autosomal dominant](#) polycystic kidney disease hyperfiltrate early in their disease. *Am J Kidney Dis* 43:624-8 [[Medline](#)]
- Wu G, Markowitz GS, Li L, D'Agati VD, Factor SM, Geng L, Tibara S, Tuchman J, Cai Y, Park JH, van Adelsberg J, Hou Jr H, Kucherlapati R, Edelmann W, Somlo S (2000) Cardiac defects and renal failure in mice with targeted [mutations](#) in Pkd2. *Nat Genet* 24:75-8 [[Medline](#)]
- Yoder BK, Hou X, Guay-Woodford LM (2002) The polycystic kidney disease [proteins](#), polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. *J Am Soc Nephrol* 13:2508-16 [[Medline](#)]
- Zerres K, Rudnik-Schoneborn S, Deget F (1993) Childhood onset [autosomal dominant](#) polycystic kidney disease in sibs: clinical picture and [recurrence risk](#). German Working Group on Paediatric Nephrology (Arbeitsgemeinschaft fur Padiatrische Nephrologie). *J Med Genet* 30:583-8 [[Medline](#)]

## Suggested Readings

- DALGAARD OZ (1957) Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families. *Acta Med Scand Suppl* 328:1-255 [[Medline](#)]
- Hildebrandt F and Otto E (2005) Cilia and centrosomes: a unifying pathogenic concept for cystic kidney disease? *Nat Rev Genet* 6:928-40 [[Medline](#)]
- Ong AC and Harris PC (2005) Molecular pathogenesis of ADPKD: the polycystin complex gets complex. *Kidney Int* 67:1234-47 [[Medline](#)]
- Torres VE and Harris PC (2006) Mechanisms of disease: [autosomal dominant](#) and [recessive](#) polycystic kidney disease. *Nat Clin Prac Nephrol* 2:40-55
- Watson ML and Torres VE (1996) Polycystic Kidney Disease, v 1. Oxford University Press, Oxford
- Wilson PD (2004) Polycystic kidney disease. *N Engl J Med* 350:151-64 [[Medline](#)]

## Author Information



Peter C Harris, PhD  
Division of Nephrology and Internal Medicine  
Mayo Clinic  
Rochester, MN

Vicente E Torres, MD  
Division of Nephrology and Internal Medicine  
Mayo Clinic  
Rochester, MN

---

**Contact**  
**GeneTests**

**Copyright© 1993-2007, All Rights Reserved**  
**University of Washington, Seattle**  
**[Terms of Use](#)**

---

**Funding Support**  
National Library of Medicine, NIH  
National Human Genome Research Institute, NIH

**Sponsoring Institution**  
[University of Washington](#)  
Seattle, Washington